Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease
暂无分享,去创建一个
M. Fiegl | P. Valent | S. Dirnhofer | W. Sperr | H. Horny | L. Escribano | I. Simonitsch-Klupp | C. Bellas | J. Jordan | H. Semper
[1] R. Valenta,et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. , 2001, Blood.
[2] P. Valent,et al. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. , 2001, Leukemia research.
[3] K. Lennert,et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.
[4] L. Scott,et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. , 2000, Blood.
[5] R. Parwaresch,et al. Recent Advances in Mastocytosis Research , 1999, International Archives of Allergy and Immunology.
[6] L. Schwartz,et al. The potential clinical utility of serum α-protryptase levels , 1999 .
[7] D. Heitjan,et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[8] N. Sepp,et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. , 1998, The Journal of investigative dermatology.
[9] D. Metcalfe,et al. Clinical correlates of the presence of the asp816Val c‐kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis , 1998, Cancer.
[10] K. Lennert,et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. , 1998, The American journal of surgical pathology.
[11] A. Órfão,et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. , 1998, Blood.
[12] A. Chott,et al. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis. , 1998, Wiener klinische Wochenschrift.
[13] A. Órfão,et al. Immunophenotypic Characterization of Human Bone Marrow Mast Cells. A Flow Cytometric Study of Normal and Pathological Bone Marrow Samples , 1998, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[14] P. Ruck,et al. Systemic mast cell disease (mastocytosis). General aspects and histopathological diagnosis. , 1997, Histology and histopathology.
[15] A. Órfão,et al. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. , 1997, Cytometry.
[16] W. Vainchenker,et al. A new c‐kit mutation in a case of aggressive mast cell disease , 1997, British journal of haematology.
[17] Laura H. Tang,et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.
[18] B. Zweiman,et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. , 1995, The Journal of clinical investigation.
[19] Y. Suzuki,et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[20] W. Travis,et al. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. , 1991, The American journal of medicine.
[21] K. Austen,et al. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. , 1991, The Journal of investigative dermatology.
[22] D. Metcalfe. The liver, spleen, and lymph nodes in mastocytosis. , 1991, The Journal of investigative dermatology.
[23] D. Metcalfe,et al. Classification and diagnosis of mastocytosis: current status. , 1991, The Journal of investigative dermatology.
[24] E. Bergstralh,et al. Systemic Mast Cell Disease: ANALYSIS OF 58 CASES AND LITERATURE REVIEW , 1988, Medicine.
[25] H. S. Earl,et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. , 1987, The New England journal of medicine.
[26] W. Travis,et al. Mast cell leukemia: report of a case and review of the literature. , 1986, Mayo Clinic proceedings.
[27] S. Eridani,et al. Mast cell leukaemia: evidence for bone marrow origin of the pathological clone , 1986, British journal of haematology.
[28] K. Lennert,et al. Bone marrow findings in systemic mastocytosis. , 1985, Human pathology.
[29] K. Lennert,et al. Tissue mast cells in health and disease. , 1985, Pathology, research and practice.
[30] S. Hsu,et al. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[31] K. Lennert,et al. Mast cells and mast cell neoplasia: a review * , 1979, Histopathology.
[32] P. Valent,et al. Biology, classification and treatment of human mastocytosis. , 1996, Wiener klinische Wochenschrift.